Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q2 2023 Novo Nordisk A/S Earnings Call Transcript

Aug 10, 2023 / 11:00AM GMT
Release Date Price: kr624 (-1.22%)
Operator

Good day, and thank you for standing by. Welcome to the Q2 2023 Novo Nordisk A/S Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Daniel Bohsen, Head of Investor Relations. Go ahead.

Daniel Bohsen;S;CVP;Head of IR
Novo Nordisk A

/-&

Thank you. Welcome to this Novo Nordisk earnings call for the first 6 months of 2023 and the outlook for the year. My name is Daniel Bohsen, and I'm Head of Investor Relations at Novo Nordisk. With me today, I have CEO of Novo Norsk, Lars Jorgensen; Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; Executive Vice President and Head of North America Operations, Doug Langa; Executive Vice President and Head of Development, Martin Holst Lange; and finally, Chief Financial Officer, Karsten Knudsen.

All speakers will be available for the Q&A session. Today's announcement and the slides for this call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot